Novo Nordisk’s Wegovy head start on pills forces investors to rethink Eli Lilly's GLP-1 dominance
Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.
What's Your Reaction?
like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0
